FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079971812> ?p ?o ?g. }

• W2079971812 endingPage "884" @default.
• W2079971812 startingPage "874" @default.
• W2079971812 abstract "Evidence on the effectiveness of respiratory syncytial virus (RSV) immunoprophylaxis with palivizumab in children with cystic fibrosis (CF) is lacking.We utilized Medicaid Extract files from 27 states from 1999 to 2006 linked to the National Cystic Fibrosis Registry to establish a cohort of children 0-2 years with CF diagnosis. Eligible children entered the cohort after CF diagnosis and after RSV season onset, and were followed until season end, second birthday, death, or hospitalizations for reasons other then the study outcome. Two outcomes were examined: hospitalization for RSV infections (RSV-ha), or hospitalization for acute respiratory infections (ARI-ha). Palivizumab exposure was defined based on pharmacy or procedure claims as current (claim date plus 30 days), former (day 31-60 after a claim), and no exposure (days before the first or >60 days after any claim). Both outcomes were examined in a Cox regression model, adjusting for RSV risk factors and CF severity via exposure propensity score.The matched cohort included 1,974 infants (2,875 infant seasons), who experienced 32 RSV-ha and 212 ARI-ha (3.9 and 26.2/1,000 season months, respectively). Compared to periods of no use, the adjusted hazard ratio for current use was 0.57 (95% confidence interval [CI]: 0.20-1.60) for RSV-related hospitalization and 0.85 (95% CI: 0.59-1.21) for ARI-related hospitalization. Each month of increasing age reduced the ARI-ha by 5.8%.RSV hospitalization incidence was low suggesting either little contribution of the virus to respiratory infections in patients with CF or lack of RSV testing. Unadjusted and adjusted RSV-hospitalization incidence rates suggested potentially positive effects of palivizumab, but results were inconclusive due to small event rates. Hospitalizations for acute respiratory illness with possible RSV contribution showed no association with palivizumab use, suggesting limited overall effect of palivizumab. Younger age greatly increased infection risk." @default.
• W2079971812 created "2016-06-24" @default.
• W2079971812 creator A5017314153 @default.
• W2079971812 creator A5042321364 @default.
• W2079971812 creator A5064006627 @default.
• W2079971812 creator A5089105344 @default.
• W2079971812 date "2012-11-08" @default.
• W2079971812 modified "2023-10-10" @default.
• W2079971812 title "Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis" @default.
• W2079971812 cites W1955367883 @default.
• W2079971812 cites W1975386460 @default.
• W2079971812 cites W1986691227 @default.
• W2079971812 cites W2007406459 @default.
• W2079971812 cites W2016383224 @default.
• W2079971812 cites W2029503764 @default.
• W2079971812 cites W2048204433 @default.
• W2079971812 cites W2051131055 @default.
• W2079971812 cites W2056291443 @default.
• W2079971812 cites W2060815380 @default.
• W2079971812 cites W2067374081 @default.
• W2079971812 cites W2068377502 @default.
• W2079971812 cites W2068992938 @default.
• W2079971812 cites W2075009759 @default.
• W2079971812 cites W2077290707 @default.
• W2079971812 cites W2079811732 @default.
• W2079971812 cites W2104682204 @default.
• W2079971812 cites W2119680872 @default.
• W2079971812 cites W2137257917 @default.
• W2079971812 cites W2139392338 @default.
• W2079971812 cites W2151246525 @default.
• W2079971812 cites W2517356996 @default.
• W2079971812 cites W4292315834 @default.
• W2079971812 doi "https://doi.org/10.1002/ppul.22711" @default.
• W2079971812 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7167886" @default.
• W2079971812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23139089" @default.
• W2079971812 hasPublicationYear "2012" @default.
• W2079971812 type Work @default.
• W2079971812 sameAs 2079971812 @default.
• W2079971812 citedByCount "28" @default.
• W2079971812 countsByYear W20799718122013 @default.
• W2079971812 countsByYear W20799718122014 @default.
• W2079971812 countsByYear W20799718122015 @default.
• W2079971812 countsByYear W20799718122016 @default.
• W2079971812 countsByYear W20799718122017 @default.
• W2079971812 countsByYear W20799718122018 @default.
• W2079971812 countsByYear W20799718122019 @default.
• W2079971812 countsByYear W20799718122020 @default.
• W2079971812 countsByYear W20799718122023 @default.
• W2079971812 crossrefType "journal-article" @default.
• W2079971812 hasAuthorship W2079971812A5017314153 @default.
• W2079971812 hasAuthorship W2079971812A5042321364 @default.
• W2079971812 hasAuthorship W2079971812A5064006627 @default.
• W2079971812 hasAuthorship W2079971812A5089105344 @default.
• W2079971812 hasBestOaLocation W20799718122 @default.
• W2079971812 hasConcept C120665830 @default.
• W2079971812 hasConcept C121332964 @default.
• W2079971812 hasConcept C126322002 @default.
• W2079971812 hasConcept C187212893 @default.
• W2079971812 hasConcept C201903717 @default.
• W2079971812 hasConcept C207103383 @default.
• W2079971812 hasConcept C2776938444 @default.
• W2079971812 hasConcept C2778644256 @default.
• W2079971812 hasConcept C44249647 @default.
• W2079971812 hasConcept C50382708 @default.
• W2079971812 hasConcept C534529494 @default.
• W2079971812 hasConcept C61511704 @default.
• W2079971812 hasConcept C71924100 @default.
• W2079971812 hasConcept C72563966 @default.
• W2079971812 hasConceptScore W2079971812C120665830 @default.
• W2079971812 hasConceptScore W2079971812C121332964 @default.
• W2079971812 hasConceptScore W2079971812C126322002 @default.
• W2079971812 hasConceptScore W2079971812C187212893 @default.
• W2079971812 hasConceptScore W2079971812C201903717 @default.
• W2079971812 hasConceptScore W2079971812C207103383 @default.
• W2079971812 hasConceptScore W2079971812C2776938444 @default.
• W2079971812 hasConceptScore W2079971812C2778644256 @default.
• W2079971812 hasConceptScore W2079971812C44249647 @default.
• W2079971812 hasConceptScore W2079971812C50382708 @default.
• W2079971812 hasConceptScore W2079971812C534529494 @default.
• W2079971812 hasConceptScore W2079971812C61511704 @default.
• W2079971812 hasConceptScore W2079971812C71924100 @default.
• W2079971812 hasConceptScore W2079971812C72563966 @default.
• W2079971812 hasIssue "9" @default.
• W2079971812 hasLocation W20799718121 @default.
• W2079971812 hasLocation W20799718122 @default.
• W2079971812 hasLocation W20799718123 @default.
• W2079971812 hasLocation W20799718124 @default.
• W2079971812 hasOpenAccess W2079971812 @default.
• W2079971812 hasPrimaryLocation W20799718121 @default.
• W2079971812 hasRelatedWork W1521115986 @default.
• W2079971812 hasRelatedWork W2009097124 @default.
• W2079971812 hasRelatedWork W2314642553 @default.
• W2079971812 hasRelatedWork W2592183814 @default.
• W2079971812 hasRelatedWork W2883825446 @default.
• W2079971812 hasRelatedWork W2906030035 @default.
• W2079971812 hasRelatedWork W2994686985 @default.
• W2079971812 hasRelatedWork W4281722959 @default.
• W2079971812 hasRelatedWork W4379796428 @default.

• next